{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T00:08:15Z","timestamp":1755907695580,"version":"3.44.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,22]]},"DOI":"10.7759\/cureus.90758","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:46:01Z","timestamp":1755881161000},"source":"Crossref","is-referenced-by-count":0,"title":["Assessment of Risk Factors for Vasoplegic Syndrome in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass"],"prefix":"10.7759","author":[{"given":"Kristin A","family":"Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi L","family":"Brink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen C","family":"Brannan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott W","family":"Lundgren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth R","family":"Lyden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quinton B","family":"Behlers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-018-2102-1","article-title":"Definitions and pathophysiology of vasoplegic shock","volume":"22","author":"Lambden S","year":"2018","unstructured":"Lambden S, Creagh-Brown BC, Hunt J, Summers C, Forni LG. Definitions and pathophysiology of vasoplegic shock. Crit Care. 2018, 22:174. 10.1186\/s13054-018-2102-1","journal-title":"Crit Care"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1053\/j.semtcvs.2010.09.007","article-title":"Vasoplegia during cardiac surgery: current concepts and management","volume":"22","author":"Fischer GW","year":"2010","unstructured":"Fischer GW, Levin MA. Vasoplegia during cardiac surgery: current concepts and management. Semin Thorac Cardiovasc Surg. 2010, 22:140-4. 10.1053\/j.semtcvs.2010.09.007","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.814533","article-title":"Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome","volume":"120","author":"Levin MA","year":"2009","unstructured":"Levin MA, Lin HM, Castillo JG, Adams DH, Reich DL, Fischer GW. Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome. Circulation. 2009, 120:1664-71. 10.1161\/CIRCULATIONAHA.108.814533","journal-title":"Circulation"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jocs.15805","article-title":"Vasoplegic syndrome after cardiovascular surgery: a review of pathophysiology and outcome-oriented therapeutic management","volume":"36","author":"Datt V","year":"2021","unstructured":"Datt V, Wadhhwa R, Sharma V, Virmani S, Minhas HS, Malik S. Vasoplegic syndrome after cardiovascular surgery: a review of pathophysiology and outcome-oriented therapeutic management. J Card Surg. 2021, 36:3749-60. 10.1111\/jocs.15805","journal-title":"J Card Surg"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.38307","article-title":"The durability of intravenous hydroxocobalamin in vasoplegia","volume":"15","author":"Blaha M","year":"2023","unstructured":"Blaha M, Blais M, Olson L. The durability of intravenous hydroxocobalamin in vasoplegia. Cureus. 2023, 15:e38307. 10.7759\/cureus.38307","journal-title":"Cureus"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.85596","article-title":"Hydroxocobalamin dosing strategies for vasoplegic syndrome post-cardiac surgery: a retrospective cohort study","volume":"17","author":"Behlers QB","year":"2025","unstructured":"Behlers QB, Buenger BK, Peitz GJ, Shostrom VK, Brannan SC. Hydroxocobalamin dosing strategies for vasoplegic syndrome post-cardiac surgery: a retrospective cohort study. Cureus. 2025, 17:e85596. 10.7759\/cureus.85596","journal-title":"Cureus"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezw316","article-title":"Incidence and predictors of vasoplegia after heart failure surgery","volume":"51","author":"van Vessem ME","year":"2017","unstructured":"van Vessem ME, Palmen M, Couperus LE, et al.. Incidence and predictors of vasoplegia after heart failure surgery. Eur J Cardiothorac Surg. 2017, 51:532-8. 10.1093\/ejcts\/ezw316","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1704154","article-title":"Angiotensin II for the treatment of vasodilatory shock","volume":"377","author":"Khanna A","year":"2017","unstructured":"Khanna A, English SW, Wang XS, et al.. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med. 2017, 377:419-30. 10.1056\/NEJMoa1704154","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-014-0534-9","article-title":"Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study","volume":"18","author":"Chawla LS","year":"2014","unstructured":"Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z, Seneff MG. Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care. 2014, 18:534. 10.1186\/s13054-014-0534-9","journal-title":"Crit Care"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1074248415587969","article-title":"Direct vasodilators and sympatholytic agents","volume":"21","author":"McComb MN","year":"2016","unstructured":"McComb MN, Chao JY, Ng TM. Direct vasodilators and sympatholytic agents. J Cardiovasc Pharmacol Ther. 2016, 21:3-19. 10.1177\/1074248415587969","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.412130","article-title":"Hydralazine and organic nitrates restore impaired excitation-contraction coupling by reducing calcium leak associated with nitroso-redox imbalance","volume":"288","author":"Dulce RA","year":"2013","unstructured":"Dulce RA, Yiginer O, Gonzalez DR, Goss G, Feng N, Zheng M, Hare JM. Hydralazine and organic nitrates restore impaired excitation-contraction coupling by reducing calcium leak associated with nitroso-redox imbalance. J Biol Chem. 2013, 288:6522-33. 10.1074\/jbc.M112.412130","journal-title":"J Biol Chem"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-010-6233-0","article-title":"Hydralazine does not ameliorate nitric oxide resistance in chronic heart failure","volume":"24","author":"Chirkov YY","year":"2010","unstructured":"Chirkov YY, De Sciscio M, Sverdlov AL, Leslie S, Sage PR, Horowitz JD. Hydralazine does not ameliorate nitric oxide resistance in chronic heart failure. Cardiovasc Drugs Ther. 2010, 24:131-7. 10.1007\/s10557-010-6233-0","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.12712","article-title":"Antihypertensive methyldopa, labetalol, hydralazine, and clonidine reversed tumour necrosis factor-\u03b1 inhibited endothelial nitric oxide synthase expression in endothelial-trophoblast cellular networks","volume":"44","author":"Xu B","year":"2017","unstructured":"Xu B, Bobek G, Makris A, Hennessy A. Antihypertensive methyldopa, labetalol, hydralazine, and clonidine reversed tumour necrosis factor-\u03b1 inhibited endothelial nitric oxide synthase expression in endothelial-trophoblast cellular networks. Clin Exp Pharmacol Physiol. 2017, 44:421-7. 10.1111\/1440-1681.12712","journal-title":"Clin Exp Pharmacol Physiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/388666-assessment-of-risk-factors-for-vasoplegic-syndrome-in-patients-undergoing-cardiac-surgery-with-cardiopulmonary-bypass","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T16:46:01Z","timestamp":1755881161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/388666-assessment-of-risk-factors-for-vasoplegic-syndrome-in-patients-undergoing-cardiac-surgery-with-cardiopulmonary-bypass"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.90758","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,22]]}}}